Inhibitory immune checkpoints in cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint inhibitors targeting PD-1 and CTLA-4 have revolutionized cancer therapy but exhibit limited efficacy in certain cancers.
• Variable patient responses and emerging complexities necessitate exploration of additional immune checkpoints as therapeutic targets.

Purpose of the Study:

• To review the complexities of inhibitory immune checkpoints beyond PD-1 and CTLA-4.
• To provide insights for developing more effective and safer immunotherapies.

Main Methods:

• Literature review of recent studies on immune checkpoint inhibitors.
• Analysis of mechanisms of action and regulation of experimental inhibitory immune checkpoints.

Main Results:

• Current immune checkpoint inhibitors have limitations in efficacy and patient variability.
• Experimental checkpoints and their targeting drugs display unexpected or undesirable mechanisms of action.
• Underappreciated complexities in immune checkpoint regulation impact therapeutic outcomes.

Conclusions:

• A deeper understanding of immune checkpoint intricacies is crucial for advancing cancer immunotherapy.
• Future therapeutic strategies must address these complexities to improve treatment effectiveness and safety.